Electra Therapeutics (NASDAQ:ETRA) Director Carl Gordon Acquires 20,000 Shares of Company Stock

Electra Therapeutics, Inc. (NASDAQ:ETRA – Get Free Report) Director Carl Gordon acquired 20,000 shares of the business’s stock in a transaction dated Monday, November 9th. The shares were acquired at an average cost of $8.24 per share, with a total value of $164,800.00. Following the acquisition, the director directly owned 5,234,578 shares of the company’s stock, valued at $43,132,922.72. This represents a 0.38% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Electra Therapeutics Stock Down 2.8%

ETRA traded down $0.23 on Tuesday, reaching $7.99. The company had a trading volume of 298,185 shares, compared to its average volume of 376,388. Electra Therapeutics, Inc. has a 52-week low of $6.86 and a 52-week high of $15.50.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. HC Wainwright started coverage on Electra Therapeutics in a research note on Monday, October 26th. They set a “buy” rating and a $30.00 price target for the company. Evercore initiated coverage on Electra Therapeutics in a research report on Tuesday, October 13th. They issued an “outperform” rating and a $36.00 target price for the company. Zacks Research raised Electra Therapeutics to a “hold” rating in a research note on Wednesday, October 14th. Cantor Fitzgerald started coverage on shares of Electra Therapeutics in a research report on Tuesday, October 13th. They set an “overweight” rating on the stock. Finally, TD Cowen began coverage on shares of Electra Therapeutics in a research note on Tuesday, October 13th. They set a “buy” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $33.50.

Read Our Latest Stock Analysis on Electra Therapeutics

About Electra Therapeutics

(Get Free Report)

Electra Therapeutics, Inc. (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function. Electra’s lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.

Read More

Insider Buying and Selling by Quarter for Electra Therapeutics (NASDAQ:ETRA)

Receive News & Ratings for Electra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.